Edgestream Partners L.P. Has $5.45 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Edgestream Partners L.P. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 361.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,373 shares of the biopharmaceutical company’s stock after acquiring an additional 8,124 shares during the quarter. Edgestream Partners L.P.’s holdings in Regeneron Pharmaceuticals were worth $5,446,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Cove Private Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after purchasing an additional 20 shares during the last quarter. Marino Stram & Associates LLC boosted its stake in Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 20 shares in the last quarter. Activest Wealth Management grew its position in Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares during the last quarter. CX Institutional raised its stake in Regeneron Pharmaceuticals by 7.9% during the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 22 shares in the last quarter. Finally, Redwood Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4.8% in the second quarter. Redwood Wealth Management Group LLC now owns 506 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 23 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Jefferies Financial Group boosted their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a research note on Wednesday, August 27th. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Sanford C. Bernstein raised their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Finally, Wells Fargo & Company boosted their price objective on Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $757.91.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $742.00 on Wednesday. The firm has a market cap of $77.98 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 2.03 and a beta of 0.37. The firm’s fifty day moving average is $641.33 and its 200-day moving average is $585.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the business posted $12.46 earnings per share. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.